Browse by author
Lookup NU author(s): Emeritus Professor Elaine Perry
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
There is an urgent need to improve the pharmacotherapy of schizophrenia despite the introduction of important new medications. New treatment insights may come from appreciating the therapeutic implications of model psychoses. In particular, basic and clinical studies have employed the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, as a probe of NMDA receptor contributions to cognition and behavior. These studies illustrate a translational neuroscience approach for probing mechanistic hypotheses related to the neurobiology and treatment of schizophrenia and other disorders. Two particular pathophysiologic themes associated with schizophrenia, the disturbance of cortical connectivity and the disinhibition of glutamatergic activity may be modeled by the administration of NMDA receptor antagonists. The purpose of this review is to consider the possibility that agents that attenuate these two components of NMDA receptor antagonist response may play complementary roles in the treatment of schizophrenia.
Author(s): Perry E; Krystal JH; D'Souza DC; Mathalon D; Belger A; Hoffman R
Publication type: Article
Publication status: Published
Journal: Psychopharmacology
Year: 2003
Volume: 169
Issue: 3-4
Pages: 215-233
ISSN (print): 0033-3158
ISSN (electronic): 1432-2072
Publisher: Springer
URL: http://dx.doi.org/10.1007/s00213-003-1582-z
DOI: 10.1007/s00213-003-1582-z
Notes: Journal Article Review
Altmetrics provided by Altmetric
